Navigation Links
Discovery may help fight late-stage ovarian cancer
Date:11/16/2011

A potential breakthrough in treating late-stage ovarian cancer has come from University of Guelph researchers who have discovered a peptide that shrinks advanced tumours and improves survival rates for this deadly but often undetected disease.

"We're extremely excited about this," said Jim Petrik, a professor in U of G's Department of Biomedical Sciences who conducted the research with PhD student Nicole Campbell. "It has the potential, particularly in ovarian cancer, to have a significant impact."

Their findings will appear in Molecular Cancer Therapeutics, published by the American Association for Cancer Research.

Ovarian cancer is the most lethal gynecological cancer. Its symptoms, which include nausea, bloating and abdominal pain, are vague and can be attributed to a number of ailments.

Often the disease remains undetected until it's well advanced, when the odds of survival are poor. "It's called the silent killer because it really does sneak up on you," Petrik said.

He and Campbell discovered that ABT-898, a peptide derived from the thrombospondin molecule, shrinks established late-stage tumours in mouse models of ovarian cancer. In addition to regressing tumours, ABT-898 essentially prunes dysfunctional blood vessels in the tumour while leaving healthy vessels intact.

Petrik explains that chemotherapy treatment relies on blood vessels to transport tumour-fighting drugs. But abnormal blood vessels inside tumours make drug delivery inefficient.

"This new treatment enhances the ability to deliver chemotherapy drugs inside of the tumour where they need to go. So in combination with chemotherapy, it has fantastic potential."

Besides shrinking tumours, ABT-898 improves survival rates because cancer cells do not have time to adapt to the treatment.

"This is crucial. Women tend to succumb to ovarian cancer because the inefficient delivery of chemotherapy drugs allows the cells to build up resistance and they no longer respond to treatment," Petrik said.

More efficient drug delivery also means doctors can administer lower amounts, alleviating many of the side effects of chemotherapy. As well, said Petrik, "this is a naturally occurring protein that we are exploiting; we are not making anything synthetic."

He hopes the research will lead to human trials and, ultimately, to the development of targeted cancer therapies.

Petrik has studied ovarian cancer for more than a decade, especially regulation of growth factors and formation of blood vessels in the ovary. A U of G faculty member since 2001, he teaches physiology and anatomy at the Ontario Veterinary College.

This latest discovery was possible because Petrik's laboratory had developed a model in which cancer cells are injected directly into healthy mouse ovaries. Ovarian cancer spontaneously occurs in about two months, allowing U of G researchers to follow tumour progression.

Most researchers rely on artificially cultured clumps of cells and immunocompromised mice that poorly mimic disease progression in normal animals.

"It provides us with a tool to ask questions like this and look at interventions such as this in a way that is far more relevant to the human disease," Petrik said.


'/>"/>

Contact: Jim Petrik
jpetrik@ovc.uoguelph.ca
519-824-4120 x54921
University of Guelph
Source:Eurekalert

Related medicine news :

1. Lab-made skin cells will aid transplantation, cancer, drug discovery research
2. Will my breast cancer spread? Discovery may predict probability of metastasis
3. Discovery of a cell mechanism that reduces effectiveness of breast cancer treatment
4. Penn receives $12.5 million from NIH to speed discovery to patient care
5. A*STAR scientists make headway for cancer treatment and cancer prevention with landmark discovery
6. New York Academy of Sciences and GMEC host forum on value of animal models in drug discovery
7. Sweet insight: Discovery could speed drug development
8. URMC and Temple announce drug discovery partnership
9. Stanford discovery may eliminate potentially lethal side effect of stem cell therapy
10. Brain tumor discovery could lead to new treatment
11. Discovery of a new mechanism of gene control that is associated with cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)...  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided ... Piedras, Puerto Rico , where the ... Following a comprehensive onsite ... structural damage, temporary loss of power and minimal water ... manufacturing operations have resumed, and the company expects to ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
Breaking Medicine Technology: